Fig. 2From: Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study GroupMean score change from randomization in EORTC QLQ-C30 Summary Score until 8 months follow-up. Horizontal bars illustrates 95% confidence intervals. Kd; Carfilzomib-dexamethasoneBack to article page